# US 2024/0201194 A1 · Methods of detecting and reducing cancer cell central nervous system colonization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201194 A1
- Document ID: US20240201194A1
- Status: Published application
- Kind: A1
- Application number: 18/477,166
- Filed: 2023-09-28
- Published: 2024-06-20
- Earliest claimed: 2017-06-30
- Assignees: National Jewish Health
- Applicants: National Jewish Health
- Inventors: Jordan Jacobelli; Scott Thompson; Jeffrey Chung
- Web page: https://patentgrep.com/patent/US20240201194A1

## CPC

- G01N 33/57595: {involving intracellular compounds}
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57505: of the blood, e.g. leukaemia
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/31: Combination therapy
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- G01N 2333/4727: Calcium binding proteins, e.g. calmodulin
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention is related to novel methods for detecting and reducing cancer cell central nervous system colonization and methods of treating subjects having cancers that colonize in the central nervous system.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of reducing leukemia relapse in a subject in need thereof, the method comprising administering to the subject, a Protocadherin-9 (PCDH9) inhibitor, wherein the PCDH9 inhibitor is selected from the group consisting of an antisense molecule, an siRNA molecule, an shRNA molecule, a B-cell directed antibody and a nanoparticle loaded with PCDH9-specific interfering RNA.

### Claim 22 (depends on 21)

The method of claim 21, wherein the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML).

### Claim 23 (depends on 21)

The method of claim 21, wherein the subject is further administered a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.

### Claim 24 (depends on 21)

The method of claim 21, wherein the subject is human.

### Claim 25

A method to inhibit or reverse hematological cancer cell colonization of the central nervous system (CNS) in a subject in need thereof, the method comprising administering to the subject, a PCDH9 inhibitor, wherein the PCDH9 inhibitor is selected from the group consisting of an antisense molecule, an siRNA molecule, an shRNA molecule, a B-cell directed antibody and a nanoparticle loaded with PCDH9-specific interfering RNA.

### Claim 26 (depends on 25)

The method of claim 25, wherein the hematological cancer is leukemia or lymphoma.

### Claim 27 (depends on 26)

The method of claim 26, wherein the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML).

### Claim 28 (depends on 25)

The method of claim 25, wherein the subject is further administered a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.

### Claim 29 (depends on 25)

The method of claim 25, wherein the subject is human.
